Merck (BUE:MRK) FFO


BUE:MRK Merck & Co Inc BUE:MRK
70 GF Score
Price ARS40,100.00
GF Value ARS35,958.34
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Merck FFO?

FFO (Funds from operations) only applies to REITs.

BUE:MRK
70GF Score
Merck & Co Inc BUE:MRK
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Merck (BUE:MRK) Overvalued in 2026?

Based on GuruFocus' analysis, Merck stock appears to be overvalued. The current stock price of ARS40,100.00 is trading 11.5% above its estimated GF Value™ of ARS35,958.34. GuruFocus considers Merck to be Modestly Overvalued.

Key valuation signals for BUE:MRK:

  • FFO:
  • GF Value™: ARS35,958.34 vs. price of ARS40,100.00 (11.5% above fair value)
  • GF Score™: 70/100 with 7 warning signs

No single metric tells the full story. See the BUE:MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Merck Business Description

Address 126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
70GF Score

Get the complete analysis for BUE:MRK

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS40,100.00
Price
ARS35,958.34
GF Value